Supplements · Sweeteners · Diets · Metabolic & Cardiometabolic
sucralose decreases insulin sensitivity
In plain terms: Does the sweetener sucralose harm how you handle blood sugar?
Contested Supplements 🔬 Includes disconfirming
Part of: • sucralose
RefutedContestedStrong support
consensus score -0.01
Unclear — evidence is mixed; any effect seems to show up mainly when paired with carbs or in certain gut-microbe types.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
5 support 5 contradict 1 tested null 4 mixed · 15 sources, 10 independent groups
What the evidence shows
Does sucralose cause insulin resistance? Genuinely contested. Acute effects are small/inconsistent (Pepino positive, but his own 2019 + Ahmad/Eckstein null). The clearest human harm appears only when sucralose is paired WITH carbohydrate (Dalenberg) or in susceptible microbiome phenotypes (Suez 2022, person-specific). Not established as a general human effect; an ideal n-of-1 CGM candidate.
The evidence (15)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Romo-Romo A, Aguilar-Salinas CA, Brito-Córdova GX, Gómez-Díaz RA, Almeda-Valdes P 2018 · Am J Clin Nutr | RCT | supports | high | Sucralose decreased insulin sensitivity in healthy subjects in a randomized controlled trial. |
| Pepino MY, Tiemann CD, Patterson BW, Wice BM, Klein S 2013 · Diabetes Care | RCT | supports | moderate | n=17 obese: sucralose before OGTT raised insulin AUC ~20%, glucose peak |
| Song J, He J, Liang Z 2026 · Journal of diabetes research | animal | supports | moderate | Pregnant mice, gestational sucralose exposure: increased GDM incidence, higher glucose, diminished insulin sensitivity vs control; gut-microbiota-mediated mechanism proposed. |
| Orku SE, Suyen G, Bas M 2023 · Nutrition | RCT | contradicts | moderate | Single-blind RCT, healthy normoglycaemic LNCS non-users (42 completers, age ~21, BMI ~20.7), 330 mL water daily for 4 weeks sweetened with saccharin, sucralose, aspartame+acesulfame-K, or plain water (arm sizes cannot-tell from abstract). HOMA-IR and Matsuda index assessed: 'no differences for glucose, insulin, GLP-1, or HbA1c levels or HOMA-IR scores ... when compared with the control group'; OGTT glucose and insulin AUC similar. Authors: 'no significant effect on glycemic response, insulin sensitivity, GLP-1 release'. Clean null for sucralose without carbohydrate at everyday doses = contradicts; small per-arm n and no carbohydrate co-ingestion (the claim's conditional scope) noted. Abstract-grade. |
| Bueno-Hernández N, Esquivel-Velázquez M, Alcántara-Suárez R, Gómez-Arauz AY, Espinosa-Flores AJ, de León-Barrera KL, Mendoza-Martínez VM, Sánchez Medina GA, León-Hernández M, Ruiz-Barranco A, Escobedo G, Meléndez G 2020 · Nutr J | RCT | mixed | low | Chronic sucralose consumption elevated serum insulin in young healthy adults (RCT), consistent with reduced insulin sensitivity. |
| Romo-Romo A, Sánchez-Tapia M, López-Carrasco MG, Guillén-Pineda LE, Brito-Córdova GX, Martagón AJ, Granados-Portillo O, Walther G, Gómez-Pérez FJ, Aguilar-Salinas CA, Tovar AR, Torres N, Almeda-Valdes P 2025 · Clinical nutrition ESPEN | RCT | supports | moderate | Healthy lean adults, sucralose 30d vs placebo (triple-blind RCT, n small, MMTT): Matsuda index insulin sensitivity fell 20.3% (significant), with reduced gut microbiota alpha-diversity. |
| Lück A, Standl F, Stich H 2026 · Journal of medicine and life | meta-analysis | mixed | low | Diabetic patients, 22-study meta-analysis (artificial sweeteners, not sucralose-isolated): insulin Hedges' g=0.50 (95% CI 0.19-0.82) in common-effects model, but not significant in random-effects model; high heterogeneity. |
| Nichol AD, Salame C, Rother KI, Pepino MY 2019 · (crossover) | RCT | contradicts | moderate | Sucralose ingestion: no consistent effect on insulin sensitivity/beta-cell (same lab as Pepino) |
| Yunker AG, Alves JM, Luo S, Angelo B, DeFendis A, Pickering TA, Monterosso JR, Page KA 2021 · JAMA Netw Open | RCT | tested-null | low | Sucralose vs sucrose altered appetite/reward responses differentially by obesity and sex; metabolic-hormonal response to sucralose not inert. |
| Thomson P, Santibañez R, Aguirre C, Galgani JE, Garrido D 2019 · Br J Nutr | RCT | contradicts | moderate | 7-day high-dose sucralose did NOT alter glycemic control, insulin resistance, or microbiome in healthy adults. |
| Ahmad SY, Friel JK, MacKay DS 2020 · Appl Physiol Nutr Metab | RCT | contradicts | moderate | Randomized double-blinded crossover, n=17 healthy normoglycaemic adults (BMI 22.9), pure sucralose 0.136 g/d (20% ADI) in water for 2 weeks: 'There was no change in insulin sensitivity after NNS treatment compared with the baseline values', and glucose, insulin, active GLP-1 and leptin AUCs 'were similar ... compared with the baseline values'. A null on the claim's own object, so contradicts; weak null - small n, comparison vs baseline, no estimates or CIs in the abstract, no carbohydrate co-ingestion, and the authors say results 'need to be tested in studies with longer durations'. |
| Dalenberg JR, Patel BP, Denis R, Veldhuizen MG, Nakamura Y, Vinke PC, Luquet S, Small DM 2020 · Cell Metab | RCT | mixed | moderate | Sucralose+carb x10d lowered insulin sensitivity; sucralose alone & carb alone = no effect |
| Suez J, Cohen Y, Valdés-Mas R, Mor U, Dori-Bachash M, Federici S, Zmora N, Leshem A, Heinemann M, Linevsky R, Zur M, Ben-Zeev Brik R, Bukimer A, Eliyahu-Miller S, Metz A, Fischbein R, Sharov O, Malitsky S, Itkin M, Stettner N, Harmelin A, Shapiro H, Stein-Thoeringer CK, Segal E, Elinav E 2022 · Cell | RCT | mixed | moderate | n=120 RCT (sub-ADL doses): sucralose impaired glycemic response, person-specific, microbiome-causal (gnotobiotic) |
| Lertrit A, Srimachai S, Saetung S, Chanprasertyothin S, Chailurkit LO, Areevut C, Katekao P, Ongphiphadhanakul B, Sriphrapradang C 2018 · Nutrition | RCT | supports | moderate | Randomized double-blind placebo-controlled crossover, n=15 healthy normoglycemic non-users (11 F, BMI 23.1): 200 mg sucralose in pills daily for 4 wk vs placebo, then 75-g OGTT and next-day IVGTT. Matsuda insulin sensitivity was LOWER after sucralose (4.69 ± 1.67 vs 5.31 ± 2.56, P < 0.005); acute insulin response lower (58.9 vs 69.94 µU/mL, P < 0.001); active GLP-1 AUC higher (P < 0.001). Authors: clinical significance needs longer follow-up. (Prior extract stating no change was wrong.) |
| Ford HE, Peters V, Martin NM, Sleeth ML, Ghatei MA, Frost GS, Bloom SR 2011 · Eur J Clin Nutr | RCT | contradicts | moderate | Oral sucralose did not stimulate GLP-1/PYY or alter glycemia in healthy normal-weight subjects in vivo despite in-vitro L-cell effects. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.